SarcoMed develops therapeutic solutions for treating chronic pulmonary inflammation. SarcoMed's lead product candidate, SM001, is a recombinant form of human deoxyribonuclease I (DNase I), with a proven mechanism of action and a differentiated clinical profile.SarcoMed was founded in 2017.